Caicun Zhou Selected Research

Erlotinib Hydrochloride (CP 358,774)

1/2019	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
1/2018	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
1/2017	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
9/2016	Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.
1/2016	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.
1/2016	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
1/2016	Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.
6/2015	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
5/2014	Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
1/2014	Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caicun Zhou Research Topics

Disease

248	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 08/2004
162	Neoplasms (Cancer) 05/2024 - 08/2004
79	Lung Neoplasms (Lung Cancer) 04/2024 - 01/2005
34	Adenocarcinoma of Lung 01/2024 - 05/2012
34	Disease Progression 01/2024 - 08/2004
31	Neoplasm Metastasis (Metastasis) 07/2023 - 10/2005
22	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023 - 01/2015
20	Adenocarcinoma 01/2022 - 01/2006
14	Brain Neoplasms (Brain Tumor) 06/2023 - 11/2014
14	Exanthema (Rash) 01/2018 - 07/2009
13	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2023 - 01/2012
8	Pneumonia (Pneumonitis) 01/2022 - 05/2012
7	Diarrhea 12/2022 - 01/2015
7	Neutropenia 01/2022 - 07/2010
6	Carcinoma (Carcinomatosis) 05/2023 - 01/2018
5	Vomiting 01/2021 - 02/2014
5	Lymphoma (Lymphomas) 01/2018 - 08/2013
5	Acne Vulgaris 01/2018 - 05/2012
4	Breast Neoplasms (Breast Cancer) 12/2020 - 12/2011
4	Circulating Neoplastic Cells 05/2020 - 08/2015
4	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2019 - 10/2009
4	Febrile Neutropenia 03/2016 - 07/2010
3	Hypertension (High Blood Pressure) 02/2024 - 08/2010
3	Malignant Pleural Effusion 01/2024 - 06/2015
3	Fatigue 01/2023 - 02/2015
3	Dyspnea (Shortness of Breath) 01/2023 - 01/2018
3	Infections 10/2021 - 03/2008
3	Hypoxia (Hypoxemia) 01/2021 - 02/2015
3	Nausea 01/2021 - 04/2014
3	Stomatitis 01/2018 - 02/2014
2	Proteinuria 02/2024 - 01/2019

Drug/Important Bio-Agent (IBA)

77	ErbB Receptors (EGF Receptor)IBA 04/2024 - 01/2006
69	Tyrosine Kinase InhibitorsIBA 01/2023 - 10/2010
50	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2018
39	Biomarkers (Surrogate Marker)IBA 12/2023 - 12/2011
29	PlatinumIBA 03/2024 - 08/2004
22	LigandsIBA 01/2023 - 10/2010
22	Gefitinib (Iressa)FDA Link 01/2021 - 08/2004
20	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 07/2009
18	B7-H1 AntigenIBA 01/2024 - 01/2016
16	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2007
13	AfatinibIBA 01/2022 - 05/2012
12	osimertinibIBA 04/2024 - 12/2014
12	CrizotinibIBA 01/2023 - 03/2014
12	Gemcitabine FDA Link 01/2022 - 08/2011
12	Pemetrexed (MTA)FDA Link 01/2021 - 12/2012
11	RNA (Ribonucleic Acid)IBA 04/2024 - 12/2010
11	DNA (Deoxyribonucleic Acid)IBA 04/2023 - 01/2006
11	Proteins (Proteins, Gene)FDA Link 12/2022 - 10/2016
11	Anaplastic Lymphoma KinaseIBA 01/2022 - 11/2012
9	Docetaxel (Taxotere)FDA Link 01/2024 - 07/2010
8	camrelizumabIBA 05/2024 - 01/2021
8	Paclitaxel (Taxol)FDA LinkGeneric 03/2024 - 03/2008
8	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 08/2011
8	icotinibIBA 01/2021 - 09/2013
7	Monoclonal AntibodiesIBA 01/2022 - 01/2018
7	Long Noncoding RNAIBA 01/2022 - 02/2015
6	Alanine Transaminase (SGPT)IBA 02/2024 - 08/2011
6	Circulating Tumor DNAIBA 01/2023 - 11/2015
6	CytokinesIBA 12/2022 - 08/2004
6	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2018
6	AntibodiesIBA 08/2021 - 02/2015
6	Bevacizumab (Avastin)FDA Link 12/2020 - 08/2010
6	Messenger RNA (mRNA)IBA 01/2018 - 12/2010
5	apatinibIBA 06/2022 - 01/2018
5	AntigensIBA 01/2021 - 01/2015
5	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 01/2018
5	Peptides (Polypeptides)IBA 04/2020 - 10/2010
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2018 - 01/2005
4	Small Cytoplasmic RNAIBA 04/2024 - 01/2021
4	Phosphotransferases (Kinase)IBA 04/2024 - 08/2013
4	alectinibIBA 01/2023 - 01/2019
4	Programmed Cell Death 1 ReceptorIBA 04/2022 - 01/2021
4	Liposomes (Liposome)IBA 01/2022 - 10/2010
4	Therapeutic UsesIBA 03/2021 - 08/2004
4	MucinsIBA 02/2021 - 01/2018
4	Cell-Free Nucleic AcidsIBA 01/2021 - 10/2016
4	Folic Acid (Vitamin M)FDA LinkGeneric 05/2020 - 08/2015
4	VaccinesIBA 04/2020 - 04/2017
4	IntegrinsIBA 11/2018 - 01/2007
4	MicroRNAs (MicroRNA)IBA 08/2018 - 01/2017
4	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2017 - 08/2013
4	Transcription Factors (Transcription Factor)IBA 05/2017 - 01/2005
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2024 - 01/2017
3	pembrolizumabIBA 08/2023 - 05/2023
3	mobocertinibIBA 01/2023 - 12/2021
3	Cancer VaccinesIBA 04/2020 - 11/2019
3	Contrast MediaIBA 11/2018 - 05/2011
3	Interleukin-6 (Interleukin 6)IBA 11/2018 - 08/2004
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 09/2016 - 01/2013
3	Codon (Codons)IBA 10/2010 - 01/2006
2	Angiogenesis InhibitorsIBA 05/2024 - 01/2019
2	famitinibIBA 05/2024 - 02/2024
2	entrectinibIBA 04/2024 - 01/2023

Therapy/Procedure

97	Drug Therapy (Chemotherapy) 04/2024 - 08/2004
92	Therapeutics 04/2024 - 02/2005
56	Immunotherapy 01/2024 - 06/2015
8	Radiotherapy 12/2020 - 10/2010
4	Molecular Targeted Therapy 02/2023 - 11/2014
2	Chemoradiotherapy 03/2024 - 01/2017